ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) today announced that The Helen F. Graham Cancer Center associated with Christiana Care Health System, a screening site for the International Early Lung Cancer Program (I-ELCAP), will recruit a cohort of patients diagnosed with lung cancer to participate in the final stage of the Phase II pilot study of the investigational CyPath® assay, an early-stage diagnostic test for lung cancer.
